Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by DIYGuyon Aug 09, 2017 12:45pm
112 Views
Post# 26561529

RE:RE:RE:Investor Event - COTI

RE:RE:RE:Investor Event - COTII am on their email list for updates. I had signed up on their website. The update says to forward to potential investors, so I thought might as well post the whole invite here.

Don't think I can make it on Tuesday, but would appreciate objective comments to anyone who attends. I believe a big dilution is inevitable but the alternative is worse. Will be interesting to see what happens to the share price after the financing goes through. Would love to see management and directors kick in their own money on the financing to show they believe in the future of their molecules in the pipeline. That would be the best promotion of their company rather than getting shares issued to them.

As a matter of fact management and directors should be required to hold a certain percentage of stock. Maybe that should be brought up (voted on)  at next annual meeting.

One other issue I have with clinical trials and how they progress is that each cohort progression should disclose if there were any toxic results in the cohort. I find it hard to believe these stay a secret the longer it progresses. The FDA should embrace more disclosure at each stage in the trial. More transparency may inject more investment in this high risk sector.
<< Previous
Bullboard Posts
Next >>